Pharming Group NV
AEX:PHARM
Pharming Group NV
Total Current Assets
Pharming Group NV
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Total Current Assets
$299.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
19%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Total Current Assets
€111.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Total Current Assets
$656m
|
CAGR 3-Years
11%
|
CAGR 5-Years
20%
|
CAGR 10-Years
11%
|
|
|
argenx SE
XBRU:ARGX
|
Total Current Assets
$5.8B
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
62%
|
|
|
Merus NV
NASDAQ:MRUS
|
Total Current Assets
$692m
|
CAGR 3-Years
23%
|
CAGR 5-Years
28%
|
CAGR 10-Years
31%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Total Current Assets
$79m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Total Current Assets?
Total Current Assets
299.5m
USD
Based on the financial report for Dec 31, 2025, Pharming Group NV's Total Current Assets amounts to 299.5m USD.
What is Pharming Group NV's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
19%
Over the last year, the Total Current Assets growth was 8%. The average annual Total Current Assets growth rates for Pharming Group NV have been 3% over the past three years , 3% over the past five years , and 19% over the past ten years .
